Argitalpenak (66) MARIA VARELA CALVO argitalpenak

2023

  1. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

    Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516

  2. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 754-763

  3. Prevalence and pattern of alcohol consumption in patients with hepatocellular carcinoma

    Medicina Clinica, Vol. 161, Núm. 2, pp. 49-53

2022

  1. Low applicability of the ''Six-and-twelve score" in hepatocellular carcinoma treated with Drug-Eluting Beads Transarterial Chemoembolization

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 1, pp. 28-34

  2. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

  3. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

    Liver International, Vol. 42, Núm. 8, pp. 1891-1901

  4. The complex management of hepatocellular carcinoma: a major need for expertise

    Revista Espanola de Enfermedades Digestivas

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  3. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  4. Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study

    Liver International, Vol. 41, Núm. 9, pp. 2200-2211

  5. Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients with Alcohol-Related Liver Cirrhosis

    American Journal of Gastroenterology, Vol. 116, Núm. 12, pp. 2390-2398

  6. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  7. Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

    Liver Transplantation, Vol. 27, Núm. 12, pp. 1767-1778

2020

  1. Efficacy and safety of the combination of pravastatin and sorafenib for the treatment of advanced hepatocellular carcinoma (Estahep clinical trial)

    Cancers, Vol. 12, Núm. 7, pp. 1-14

  2. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

  3. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization

    BMC Gastroenterology, Vol. 20, Núm. 1

2019

  1. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

    American Journal of Transplantation, Vol. 19, Núm. 11, pp. 3176-3184

  2. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

    Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884

2018

  1. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR

    Oncotarget, Vol. 9, Núm. 56, pp. 30869-30882